Tags

Type your tag names separated by a space and hit enter

Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Clin Ther. 2003 Oct; 25(10):2597-608.CT

Abstract

BACKGROUND

Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies.

OBJECTIVE

This article reviews available data on the use of the newer AED gabapentin for the control of PHN.

METHODS

A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia.

RESULTS

The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog(P < 0.001) and Likert scales (P < 0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health(P < 0.01).

CONCLUSION

Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN.

Authors+Show Affiliations

Pain Management Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. staceyb@ohsu.eduNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

14667960

Citation

Stacey, Brett R., and Robert L. Glanzman. "Use of Gabapentin for Postherpetic Neuralgia: Results of Two Randomized, Placebo-controlled Studies." Clinical Therapeutics, vol. 25, no. 10, 2003, pp. 2597-608.
Stacey BR, Glanzman RL. Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. Clin Ther. 2003;25(10):2597-608.
Stacey, B. R., & Glanzman, R. L. (2003). Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. Clinical Therapeutics, 25(10), 2597-608.
Stacey BR, Glanzman RL. Use of Gabapentin for Postherpetic Neuralgia: Results of Two Randomized, Placebo-controlled Studies. Clin Ther. 2003;25(10):2597-608. PubMed PMID: 14667960.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. AU - Stacey,Brett R, AU - Glanzman,Robert L, PY - 2003/12/12/pubmed PY - 2004/1/21/medline PY - 2003/12/12/entrez SP - 2597 EP - 608 JF - Clinical therapeutics JO - Clin Ther VL - 25 IS - 10 N2 - BACKGROUND: Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies. OBJECTIVE: This article reviews available data on the use of the newer AED gabapentin for the control of PHN. METHODS: A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia. RESULTS: The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog(P < 0.001) and Likert scales (P < 0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health(P < 0.01). CONCLUSION: Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/14667960/Use_of_gabapentin_for_postherpetic_neuralgia:_results_of_two_randomized_placebo_controlled_studies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S014929180380320X DB - PRIME DP - Unbound Medicine ER -